CEM/C2 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119)
CEM/C2 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119).
The cell line was selected and subcloned in 1991 for resistance to CPT.
The cells are approximately 970-fold less sensitive to CPT than the parental CEM cells.
CEM/C2 cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT.
CEM/C2 cells are also cross resistant to etoposide, dactinomycin, bleomycin, mitoxantrone, 4'-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloid vincristine.
CEM/C2 cells display atypical multidrug resistance (MDR), altered topoisomerase I catalytic activity and a unique topoisomerase I mutation (Asn722Ser).
Resistance to CPT is stable for up to six months.